TITLE

NEW DATA FOR PROGRESSION ON ACTIVE SURVEILLANCE; METASTASES IN CRPC

AUTHOR(S)
So, Alan
PUB. DATE
May 2013
SOURCE
Oncology Exchange;May2013, Vol. 12 Issue 2, p28
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article focuses on the results of two clinical trials on prostate cancer presented at the American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium held on February 14-16, 2013 in Orlando, Florida. The first study emphasizes the importance of followup care in prostate cancer patients on active surveillance (AS). The second study examines the pattern of metastatic disease in castration-resistant prostate cancer (CPRC).
ACCESSION #
88033151

 

Related Articles

  • Side Effects Data, Too, Impress For New Prostate Cancer Drugs. Breindl, Anette // BioWorld Today;2/1/2012, Vol. 23 Issue 12, p1 

    This article reports on the presentation of data from the clinical trials of prostate cancer drugs from Medivation Inc. and Algeta ASA at the 2012 Genitourinary Cancers Symposium held by the American Society of Clinical Oncology (ASCO). The prostate cancer drugs involved are Medivation Inc.'s...

  • Hazard ratios are potential biohazards. Raghavan, Derek // Hem/Onc Today;7/25/2014, Vol. 15 Issue 14, p3 

    The author discusses studies presented by researchers on prostate cancer at 2014 American Society of Clinical Oncology (ASCO) Annual Meeting which was said to be a paradigm-shifting aggregation of progress in clinical cancer research and practice.

  • New Biologic Agent May Benefit Men with CRPC. Schieszer, John // Renal & Urology News;Aug2010, Vol. 9 Issue 8, p4 

    The article reports on the study about a novel biologic agent that may significantly slow the rate of disease progression and improve progression-free survival in patients with metastatic castrationresistant prostate cancer (CRPC) that was presented at the American Society of Clinical Oncology...

  • GLOBAL PARTNERS DEVELOP PROSTATE CANCER DRUG.  // Worldwide Biotech;Apr2014, Vol. 26 Issue 4, p5 

    The article focuses on the global clinical drug trial for treatment of prostate cancer which was carried out throughout the world at centers in the U.S., Canada and Australia. The development of the cancer drug was based on the three clinical trials performed by the Clinical Program on...

  • GPC Biotech/Pharmion: satraplatin edges closer to approval.  // PharmaWatch: Monthly Review;Aug2007, Vol. 6 Issue 8, p7 

    The article reports on the submission of a marketing authorization application (MAA) of Pharmion Corp. to the European Medicines Agency (EMEA) for satraplatin in combination with prednisone for the treatment of hormone refractory prostate cancer (HRPC). Satraplatin is an orally administered...

  • Investigational Drug Shows Promise for CRPC. Schieszer, John // Renal & Urology News;Sep2010, Vol. 9 Issue 9, p24 

    The article offers information on the data showed at the annual meeting of the American Society of Clinical Oncology which reveals that the investigational drug Alpharadin may relieve pain and enhance the survival of patients with castration-resistant prostate cancer (CRPC).

  • ASCO and CCO issue new prostate cancer treatment guidelines.  // PharmacoEconomics & Outcomes News;Sep2014, Vol. 712 Issue 1, p1 

    The article reports on the issuance of prostate cancer treatment guidelines by the American Society of Clinical Oncology (ASCO) and government agency Cancer Care Ontario (CCO) in 2014.

  • Novel CRPC Drug Lowers Mortality.  // Renal & Urology News;Jul2012, Vol. 11 Issue 7, p9 

    The article focuses on the study reported at the American Society of Clinical Oncology 2012 annual meeting which shows that there was an association between the increase of overall survival in patients with castration-resistant prostate cancer (CRPC) with the treatment of investigational drug...

  • Active Biotech and Ipsen to Present Tasquinimod Phase II Overall Survival Data at the 2012 ASCO Annual Meeting.  // Biomedical Market Newsletter;5/18/2012, Vol. 21, p1 

    The article offers information on the scientific conference titled "2012 American Society of Clinical Oncology (ASCO) Annual Meeting" to be held from June 1-5, 2012 in Chicago, Illinois which will feature the presentations by Active Biotech AB and Ipsen on the prostate cancer drug.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics